Quercetin

Drug Profile

Quercetin

Alternative Names: Isoquercetin; Q Force; QB3C; QU995; Quercetin-3-O-glucoside

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator Beijing Chemical Reagent Factory; Catholic University of the Sacred Heart - Rome; Farr Laboratories LLC; Indiana University School of Medicine; Quercegen Pharmaceuticals; Singapore General Hospital; SRI International; Taiyuan Pharmaceutical Factory; University of Birmingham; University of California at Los Angeles; University of Ulster
  • Developer Dana-Farber Cancer Institute; National Institutes of Health (USA); Quercegen Pharmaceuticals; University of Michigan
  • Class Flavonoids; Small molecules
  • Mechanism of Action Antioxidants; Enzyme inhibitors; Free radical scavengers; Platelet aggregation inhibitors; Prostaglandin synthase stimulants; Protein tyrosine kinase inhibitors; Thromboxane A2 synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Thromboembolism
  • Phase I/II Chronic obstructive pulmonary disease
  • Discontinued Atherosclerosis; Cancer; Cardiovascular disorders; Prostatitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 08 Dec 2016 M. D. Anderson Cancer Center plans a phase 0 trial for Chemotherapy induced neuropathic pain in USA (NCT02989129)
  • 01 Jan 2015 Phase-II/III clinical trials in Thromboembolism (Prevention) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top